On July 20, Avalo Therapeutics Entered Non-Binding LOI For Potential Sale Of AVTX-801, AVTX-802 And AVTX-803; Pursuant To LOI, Co Would Sell 800 Series For Upfront Payment Of $150,000
Portfolio Pulse from Happy Mohamed
Avalo Therapeutics has entered a non-binding Letter of Intent (LOI) for the potential sale of AVTX-801, AVTX-802, and AVTX-803. According to the LOI, the company would sell the 800 series for an upfront payment of $150,000.
July 21, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Avalo Therapeutics is considering selling its 800 series for an upfront payment of $150,000. This could potentially impact the company's financial position and future revenue streams.
The potential sale of the 800 series could bring in immediate cash for Avalo Therapeutics, but it could also mean the loss of future revenue if these assets were to generate income. The impact on the stock price is uncertain as it would depend on the market's perception of this move.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100